Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.65 |
| ▸ | CTSB | P07858 | 5/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.55 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8713258 | 1.00 | CTSL (0.65) | CTSLCTSBTGM2ITGB3ITGA2B | |
| SCHEMBL11144067 | 1.00 | CTSL (0.65) | CTSLCTSBTGM2ITGB3ITGA2B | |
| SCHEMBL11138908 | 1.00 | CTSL (0.65) | CTSLCTSBTGM2ITGB3ITGA2B | |
| SCHEMBL8433969 | 0.93 | CTSL (0.62) | CTSLCTSBTGM2P2RX7ITGA4 | |
| SCHEMBL8436808 | 0.93 | CTSL (0.62) | CTSLCTSBTGM2P2RX7ITGA4 | |
| SCHEMBL8433892 | 0.93 | CTSL (0.62) | CTSLCTSBTGM2P2RX7ITGA4 | |
| SCHEMBL18228994 | 0.91 | CTSL (0.64) | CTSLCTSB | |
| SCHEMBL10445399 | 0.91 | CTSL (0.65) | CTSLCTSB | |
| SCHEMBL10445398 | 0.91 | CTSL (0.65) | CTSLCTSB | |
| SCHEMBL7325251 | 0.89 | ITGB3 (0.58) | CTSLCTSBITGB3ITGA2BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1881982-B1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8569426-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5677282-A | ENZYME INHIBITOR; OSTEOARTHRITIS AND RHEUMATIC DISORDERS | PROSCRIPT, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5635527-A | ANTAGONIST OF PLATELET MEMBRANE GLYCOPROTEIN; TREATMENT OF THROMBOTIC DISEASES | THE GREEN CROSS CORPORATION (JP) | 1997-06-03 | — | — | US | disclosed |
| WO-1996040745-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0712844-A1 | NOVEL FUSED-RING CARBOXYLIC ACID COMPOUND OR SALT THEREOF, AND MEDICINAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | CTSL 1722/4885CTSB 635/4885TGM2 257/4885 |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | CTSL 1722/4885CTSB 635/4885TGM2 257/4885 |
| US-20130338164-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | CTSL 2709/4885CTSB 3202/4885TGM2 1514/4885 |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | CTSL 2709/4885CTSB 3202/4885TGM2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.